st international meeting integrated management of acute ... · liraglutid injektion *...
TRANSCRIPT
ORGANIZERS:KURT HUBER
(Austria)
HARALD DARIUS (Germany)
BERNARD GERSH (USA)
CHRIS GRANGER(USA)
OTMAR PACHINGER (Austria)
Innsbruck, AustriaAustria Trend Congress Hotel
January 25-28, 2020
21st International Meeting
Integrated Management of Acute and Chronic Cardiovascular Diseases
– From Prevention to Intervention
MAIN TOPICS:
Acute Coronary Syndromes
Acute Cardiovascular Care
Antiplatelet Agents
Antithrombotic Therapy
Atrial Fibrillation
Biomarkers
Case Presentations
Heart Failure
Interventional Cardiology
Master Lectures
Prevention
Structural Heart Disease
Translational Medicine (Abstracts)
F I N A LP R O G R A M
www.cardio-congress.com
ORGANIZERS:KURT HUBER
(Austria)
HARALD DARIUS (Germany)
BERNARD GERSH (USA)
CHRIS GRANGER(USA)
1
PREFACE
This international meeting celebrates its 21st anniversery. As in the past, themeeting is organized by the Association for the Promotion of Research inArteriosclerosis, Thrombosis and Vascular Biology (ATVB), Vienna, Austria. Itis patronized by the European Platelet Academy (EPA), and the AcuteCardiovascular Care Association (ACCA), a registered branch of theEuropean Society of Cardiology (ESC) as well as by the Sigmund FreudUniversity, Faculty of Medicine and the Austrian Heart Foundation.
In 2020, more than 40 international and national experts will guarantee aninteresting conference with important topics illustrating the most con temporary and topical clinical research data mainly in the field of acutecoronary syndromes, acute cardiac care, atrial fibrillation, interventional cardiology, heart failure and prevention. Master lectures and interactive clinical case discussions will extend our knowledge and enhance the practical relevance of the program.
The number of attendees is limited to a maximum of 100 persons in order tostimulate intense discussions with international and national experts on casepresentations and main topics – a rare situation in the current era of largemeetings.
The presenters of the best abstracts (a maximum of 18 abstracts will beaccepted) will discuss their data with faculty members in moderated posterpresentations. Two awards will be given for “best-of-translational medicine”and “best-of-clinical medicine” posters. The participants will be confined tothe group of young “cardiologists of tomorrow”. In addition, presenters ofposters will have free access to the whole meeting.
We would welcome your participation at this meeting.
With best regards
Kurt Huber(for the organizers)
DEADLINE FOR ABSTRACT SUBMISSIONJanuary 15, 2020
(send your abstracts, A4 format, directly to [email protected])
Sigmund FreudPrivatuniversitätWien Österreichischer Herzfonds
Liraglutid Injektion
* GLP-1-RA-Unterstützte Therapie. ** Bei Patienten mit Typ-2-Diabetes und manifester atherosklerotischer kardiovaskulärer Erkrankung sollte die antihyperglykämische Therapie […] eine Substanz beinhalten, die nachweislich schwerwiegende kardiovaskuläre Ereignisse und die kardiovaskuläre Mortalität reduziert (derzeit Empaglifl ozin und Liraglutid) [Evidenzgrad A].
1. American Diabetes Association. Diabetes Care. 2018;41(Suppl 1):S73-S85. 2. Victoza® Fachinformation Stand 10/2019. 3. Marso SP et al. N Engl J Med. 2016;375(4):311-322. 4. Pratley R et al. Int J Clin Pract. 2011;65(4):397-407.5. Nauck M et al. Diabetes Care. 2016;39(9):1501-1509. 6. Buse JB et al. Lancet. 2013;381(9861):117-124. 7. Pratley RE et al. Lancet Diabetes Endocrinol. 2014;2(4):289-297. 8. Buse JB et al. Lancet. 2009;374(9683):39-47. 9. Dungan KM et al. Lancet. 2014;384(9951):1349-1357. 10. Pratley RE et al. Lancet. 2010;375(9724):1447-1456.
Victoza® 6 mg/ml Injektionslösung in einem Fertigpen. Qualitative und quantitative Zusammensetzung: 1 ml Lösung enthält 6 mg Liraglutid*. 1 Fertigpen enthält 18 mg Liraglutid in 3 ml. * Analogon zu humanem Glucagon-like peptide-1 (GLP-1), gentechnisch hergestellt durch rekombinante DNS-Technologie in Saccharomyces cerevisiae. Vollständige Aufl istung der sonstigen Bestandteile, siehe Abschnitt 6.1. Liste der sonstigen Bestandteile: Natriummonohydrogenphosphat-Dihydrat, Propylenglycol, Phenol, Wasser für Injektionszwecke. Anwendungsgebiete: Victoza® wird zur Behandlung des unzureichend kontrollierten Diabetes mellitus Typ 2 bei Erwachsenen, Jugendlichen und Kindern ab dem Alter von 10 Jahren als Zusatz zu Diät und körperlicher Aktivität angewendet: - als Monotherapie, wenn die Anwendung von Metformin aufgrund einer Unverträglichkeit oder Kontraindikation ungeeignet ist, - zusätzlich zu anderen Arzneimitteln zur Behandlung des Diabetes mellitus. Für Studienergebnisse hinsichtlich Kombinationen, Auswirkungen auf die glykämische Kontrolle und kardiovaskuläre Ereignisse, sowie die untersuchten Populationen, siehe Abschnitte 4.4, 4.5 und 5.1. Gegenanzeigen: Überempfi ndlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 genannten sonstigen Bestandteile. Pharmako-therapeutische Gruppe: Antidiabetika, Glucagon-like-Peptid-1-(GLP-1)-Rezeptoragonisten. ATC-Code: A10BJ02. Inhaber der Zulassung: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Dänemark. Rezept- und apotheken-pfl ichtig. Stand der Information 10/2019. Weitere Angaben zu besonderen Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit sowie Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation. Adresse: Novo Nordisk Pharma GmbH, DC Tower, Donau-City-Straße 7, 1220 Wien, Tel.: 01/405 15 01-0.
Victoza® ist eine eingetragene Marke der Novo Nordisk A/S, Dänemark. 2019 © Novo Nordisk Austria.
Richtig GUT *
nur mit Victoza® ** 1
Prävention von CV-
Ereignissen 2, 3
Unübertroffene HbA1c-
Senkung4-10
Überlegene Gewichts-
reduktion4-10
AT19VZ00070
3
FINAL PROGRAM
Saturday, January 25, 2020Arrivals
19:30 Welcome Cocktail and Get-Together Evening
Sunday, January 26, 202009:00 – 08:45 Welcome and Obituary Prof. Dr. Otmar Pachinger
K. Huber (AT)
09:00 – 11:00 Symposium 1: New Antiplatelet Strategies –Answers and New Questions(partially supported by AstraZeneca)*chairs: D. Gulba (DE), A. Bauer (AT)
09:00 – 09:15 Case Presentation #1H. Alber (AT)
09:15 – 09:30 The THEMIS trial: Implications for Routine ClinicalPractice?H. Darius (DE)
09:30 – 09:45 ISAR REACT-5: The Resurrection of Prasugrel?S. Schüpke (DE)
09:45 – 10:00 Case Presentation #2C. Kaulfersch (AT)
10:00 – 10:15 TWILIGHT – Sunset for DAPT?K. Huber (AT)
10:15 – 10:45 The Future of Antiplatelet Therapy: View of a StatesmanF.W.A. Verheugt (NL)
10:45 – 11:00 Case Presentation #3J. Auer (AT)
11:00 – 11:30 Break, Exhibition
* AstraZeneca has provided a sponsorship grant towards this independent Programme
4
FINAL PROGRAM
Sunday, January 26, 2020
11:30 – 12:30 Symposium 2: Beyond Statins – New Add-OnTherapies to Lower LDL-C in High Risk Patients(supported by Daiichi Sankyo) chairs: H. Alber (AT), K. Huber (AT)
11:30 – 11:55 Management of Patients with Dyslipidemia:Importance to Reach the New LDL-C GuidelineGoals H. Drexel (AT)
11:55 – 12:20 Emerging Treatment Options for LDL-C Lowering onthe HorizonH. Toplak (AT)
12:20 – 12:30 Panel Discussion
12:30 – 13:30 Lunch Break, Exhibition,
Moderated Posters A(moderators: A. Bauer, AT, P. Clemmensen, DK, S. De Waha, DE, D. Gulba, DE, S. Schüpke, DE, J. Wojta, AT)
13:30 – 14:45 Symposium 3: Advances in Risk FactorModificationchairs: J. Deanfiled (UK), S. Price (UK)
13:30 – 13:50 Renal Denervation: The Rise and Fall and PossibleResurrectionM. Böhm (DE)
13:50 – 14:10 Anti-Inflammatory Agents – Status 2020C. Granger (US)
14:10 – 14:30 The Role of SGLT2-Inhibtors and GLP1-RA in theNew Diabetes GuidelinesH. Schühlen (DE)
14:30 – 14:45 Case Presentation #4D. Gualandro (CH)
FINAL PROGRAM
Sunday, January 26, 2020
14:45 – 16:15 Symposium 4: Controversies in InterventionalCardiologychairs: U. Zeymer (DE), S. Kristensen (DK)
14:15 – 14:45 Pre-hospital Initiation of P2Y12-Inhibition IsEssential in ACSPro: C. Granger (US) Con: K. Huber (AT)
14:45 – 15:15 Radial Is the Best Puncture SitePro: R. Welsh (CD)Con: B. Meier (CH)
15:15 – 16:15 CTO Procedures Benefit Our PatientsPro: S. Harb (AT)Con: A. Zirlik (AT)
16:15 – 16:35 Break, Exhibition
16:35 – 18:00 Symposium 5: Master Lectures Ichairs: H. Darius (DE), M. Böhm (DE)
16:35 – 16:55 The Top 5 Trials of 2019S. Pocock (UK)
16:55 – 17:15 The Ischemia Trial – Will It Change the Indications?F.W.A. Verheugt (NL)
17:15 – 17:40 Impact of Socioeconomic Status on CV Disease:Wealth is Health? B. Gersh (US)
17:40 – 18:00 Pulmonary Hypertension. Therapeutic Strategies 2020I. Lang (AT)
18:00 – 18:30 Allan Ross Memorial Lecturechair: C. Granger (US)CV Disease Prevention: Problems Ahead and LostOpportunities Behind!J. Deanfield (UK)
20:00 Networking Evening
5
FINAL PROGRAM
Monday, January 27, 2020
09:00 – 11:00 Symposium 6: Structural Heart Diseasechairs: H. Schühlen (DE), I. Lang (AT)
09:00 – 09:15 Case Presentation #5G. Friedrich (AT)
09:15 – 09:40 Functional Mitral Regurgitation: The Presence andthe Future B. Gersh (US)
09:40 – 10:05 Current Status of Mitral and Tricuspid ValveInterventionsH. Thiele (DE)
10:05 – 10:20 Case Presentation #6G. Lamm (AT)
10:20 – 10:40 Management of Conduction Abmormalites afterTAVI: When to Pace, When to ObserveU. Zeymer (DE)
10.40 – 11:00 Is There Still a Role for Surgery after the TAVISuccess Story?R. Welsh (CD)
11:00 – 11:30 Break, Exhibition
11:30 – 12:30 Symposium 7: Update in Rhythmology 2020chairs: A. Zirlik (AT), H. Darius (DE)
11:30 – 11:55 New Developments in ArrhythmiasM. Borggrefe (DE)
11:55 – 12:10 Case Presentation #7A. Rab (AT)
11:50 – 12:10 Perioperative Atrial Fibrillation: Transient andBenign or a Major Long-term ProblemB. Gersh (US)
12:10 – 12:30 ICD Implantation: Changing Indications in Ischemicand Non-ischemic CMP M. Borggrefe (DE)
12:30 – 13:30 Lunch Break, Exhibition, Moderated Posters B(moderators: J. Auer, AT, P. Clemmensen, DK, S. De Waha, DE, D. Gulba, DE, S. Schüpke, DE,J. Wojta, AT)
7
FINAL PROGRAM
Monday, January 27, 2020
13:30 – 14:30 Symposium 8: Faster, Safer and Cost Efficient inAcute Cardiac diseases: Instant ACS-rule-outand Better Risk Stratification Using the DualMarker Strategy with (hs)Troponin und Copeptin (supported by BRAHMS/Thermofisher)chairs: H. Thiele (DE), K. Huber (AT)
13:30 – 13:55 Copeptin in Acute and Cardiac Diseases. Diagnosis,Risk Stratification and PrognosisM. Möckel (DE)
13:55 – 14:20 Current Evidence of the Dual Marker ACS-rule-outStrategy. Latest Data from a Pooled AnalysisE. Giannitsis (DE)
14:20 – 14:30 Panel Discussion
14:30 – 15:30 Symposium 9: ECG Pearlsmoderated and presented by M. Borggrefe (DE)
15:30 – 16:00 Break, Exhibition
16:00 – 17:40 Symposium 10: Master Lectures II chairs: R. Welsh (CD), H. Thiele (DE)
16:00 – 16:25 New Developments in Heart FailureM. Böhm (DE)
16:25 – 16:50 The Journals: How They Mess Us UpS. Pocock (UK)
16:50 – 17:15 New Developments In CT and MR ImagingU. Sechtem (DE)
17:15 – 17:40 The ESC 2019 Guidelines on Chronic CoronarySyndromes – An OverviewS. Kristensen (DK)
17:40 – 18:10 Special Invited Lecturechair: S. Price (UK)The Myriad of Miracles and Myths ofInterventional CardiologyB. Meier (CH)
20:00 Faculty Evening
9
FINAL PROGRAM
Tuesday, January 28, 2020
09:00 – 11:05 Symposium 11: Controversies in AcuteCardiovascular Care(patronized by ACCA)chairs: V. Gasparovic (HR), S. Price (UK)
09:00 – 09:15 Case Presentation #8E. Wessely (AT)
09:15 – 09:45 The Future of IMPELLA Is EncouragingPro: P. Clemmensen (DK)Con: H. Thiele (DE)
09:45 – 10:00 Case Presentation #9A. Bauer (AT)
10:00 – 10:25 Primary PCI for All – Reality or Wishful Thinking?R. Welsh (CD)
10:25 – 10:45 Update in Cardiogenic ShockU. Zeymer (DE)
10:45 – 11:05 The 10 Do’s and Dont’s in Acute CV CareS. Price (UK)
11:05 – 11:30 Break, Exhibition
11:30 – 12:30 Symposium 12: Silent Diseases, HugeConsequences(supported by Boehringer-Ingelheim)chair: H. Darius (DE)
11:30 – 11:55 DAT vs TAT in patients with Afib undergoing PCIK. Huber (AT)
11:55 – 12:20 Gliflozines: A General Perspective in Diabetes andHeart FailureC. Granger (US)
12:20 – 12:30 Panel Discussion
12:30 – 13:30 Lunch Break, Exhibition, Moderated Posters C(moderators:, P. Clemmensen, DK, S. De Waha, DE,D. Gulba, DE, S. Farhan, US, J. Wojta, AT)
10
11
FINAL PROGRAM
Tuesday, January 28, 2020
13:30 – 14:30 Symposium 13: How to Implement the ESC 0/1h-Algorithmmoderators: S. De Waha (DE), C. Granger (US)
13:30 – 13:50 Are All Hs-cTnT/I Assays Equal C. Müller (CH)
13:50 – 14:10 First Point-of Care Hs-cTnI Assay: Ready for PrimeTime? T. Nestelberger (CH)
14:10 – 14:30 Tips & Tricks for the Implementation C. Müller (CH)
14:30 – 15:10 Symposium 14: Invited Lectureschairs: C. Müller (CH), V. Gasparovic (HR)
14:30 – 14:50 Sick-day Drugs in CV DiseasesM. Säemann (AT)
14:50 – 15:10 PCI vs. CABG for LMCA Disease: Controversy or DistractionB. Gersh (US)
15:10 – 16:10 Symposium 15: A Potpourri of Interesting Caseschairs: U. Zeymer (DE), A. Zirlik (AT)
15:10 – 15:30 Germany (Case Presentation #10 and #11)H. Schühlen (DE), H. Thiele (DE)
15:30 – 15:50 Denmark (Case Presentation #12 and #13)S. Kristensen (DK). P. Clemmensen (DK)
15:50 – 16:10 Canada and USA (Case Presentation #14 and #15)R. Welsh (CD), B. Gersh (US)
16:10 – 16:25 Poster Awards & FarewellK. Huber (AT)
16:25 End of Meeting
12
SUNDAY, January 26, 2020, 12:30 – 13:30 p.m.
Moderators: A. Bauer (AT), P. Clemmensen (DK), S. De Waha (DE), D. Gulba (DE), S. Schüpke (DE), J. Wojta (AT)
A/1Neuregulin-1 During Acute Myocardial Infarction and its Associationwith Monocyte SubsetsPaul M. Haller, Bernhard Jäger, Inês Fonseca Concalves, Eylem Acar, Edita Piackova, Claudia Wegberger, Johann Wojta, Bruno Podesser, Attila Kiss, Kurt Huber (Hamburg, DE; Vienna, AT)
A/2Combined Biomarker Risk Stratification with High-SensitivityTroponin T and N-Terminal Pro Brain Natriuretic Peptide in 3595Patients with Severe Aortic Stenosis Admitted for Valve ReplacementFabian Barbieri, Thomas Senoner, Agne Adukauskaite, Stephan Dobner, Johannes Holfeld, Severin Semsroth, Thomas Lambert, David Zweiker, Thomas Theurl, Peter Paul Rainer, Albrecht Schmidt, Gudrun MariaFeuchtner, Clemens Steinwender, Uta Hoppe, Florian Hintringer, Axel Bauer, Silvana Müller, Michael Grimm, Bernhard Erich Pfeifer,Wolfgang Dichtl (Innsbruck, AT; Berne, CH; Linz, AT; Graz, AT; Salzburg, AT; Hall, AT)
A/3Direct Comparison of the Safety and Efficacy of the ESC 0/1h-algorithmand the High-STEACS pathway for Early-Rule Out of MyocardialInfarctionPedro Lopez-Ayala, Jasper Boeddinghaus, Ivo Strebel, Luca Koechlin, Paul David Ratmann, Thomas Nestelberger, Desiree Wussler, Joan Walter, Tobias Zimmermann, Maria Rubini-Gimenez, Oscar Miro, Francisco Javier Martin-Sanchez, Jiri Parenica, Damian Kawecki, Dagmar Keller, Raphael Twerenbold, Christian Mueller (Basel, CH; Madrid, ES; Brno, CZ; Zabre, PL; Zurich, CH)
MODERATED POSTERS A
13
A/4Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9(PCSK-9) are Associated with Monocyte Subsets in Patients withStable Coronary Artery Disease Konstantin A. Krychtiuk, Max Lenz, Philipp J. Hohensinner, Stefan P. Kastl, Stefan Pfaffenberger, Sebastian L. Hofbauer, Kurt Huber,Christian Hengstenberg, Johann Wojta, Walter S. Speidl (Wien, AT)
A/5Pregnancy-Associated Plasma Protein A as a Mortality Predictor in Non-Heparinized Chest Pain PatientsT. Andric, M. Tscharre, M. Tajsic, M. Kassem, K. Huber (Wien, AT; Wiener Neustadt, AT; Berlin, DE)
A/6Influence of Myocardial Damage on Serum Procalcitonin in ST-Elevation Myocardial InfarctionMartin Reindl, Christina Tiller, Magdalena Holzknecht, Ivan Lechner, Benjamin Henninger, Agnes Mayr, Christoph Brenner, Gert Klug, Axel Bauer, Bernhard Metzler, Sebastian J. Reinstadler (Innsbruck, AT)
A/7Serum Ceramide Ratios Predict Cardiovascular Events in Patients withType 2 Diabetes Independently from the Presence of Coronary ArteryDiseaseAndreas Leiherer, Axel Muendlein, Christoph H. Saely, Rejo Laaksonen, Mitja Laaperi, Alexander Vonbank, Barbara Larcher, Arthur Mader, Maximilian Mächler, Peter Fraunberger, Heinz Drexel (Feldkirch, AT;Triesen, LI; Espoo, FL; Berne, CH; Philadelphia, US)
MODERATED POSTERS A
14
MODERATED POSTERS B
MONDAY, January 27, 2020, 12:30 – 13:30 p.m.
Moderators: J. Auer (AT), P. Clemmensen (DK), S. De Waha (DE), D. Gulba (DE), S. Schüpke (DE), J. Wojta ( AT)
B/1Etiology of Perioperative Myocardial Infarctions/Injuries after Non-Cardiac Surgery and Associated OutcomesChristian Puelacher, Danielle M. Gualandro, Giovanna Lurati Buse, Stella Marbot, Johanna Gückel, Marcel Liffert, Ketina Arslani, Christoph Kindler, Jaqueline Espinola, Andreas Lampart, Stefan Osswald,Christian Mueller, BASEL-PMI Investigators (Basel, CH; Sao Paulo, BR;Duesseldorf, DE; Aarau, CH; Berne, CH)
B/2Monocyte Subset Distribution is Associated with Outcome in PatientsAfter Cardiac ArrestKonstantin A. Krychtiuk, Max Lenz, Kurt Huber, Christian Hengstenberg,Johann Wojta, Gottfried Heinz, Walter S. Speidl (Wien, AT)
B/3Clinical Risk Score for Prediction of Early Left Ventricular Thrombusafter Percutaneous Coronary Intervention for ST-ElevationMyocardial InfarctionSebastian Johannes Reinstadler, Magdalena Holzknecht, Martin Reindl,Christina Tiller, Ivan Lechner, Agnes Mayr, Christoph Brenner, Gert Klug,Axel Bauer, Bernhard Metzler (Innsbruck, AT)
B/4The Branched-Chain Amino Acids Valine and Leucine Predict All-Cause Mortality in Cardiovascular Disease Patients Independently From the Presence of Type 2 Diabetes MellitusAxel Muendlein, Andreas Leiherer, Christoph H. Saely, Alexander Vonbank, Marc Schindelwolf, Jörn F. Dopheide, Iris Baumgartner, Barbara Larcher, Arthur Mader, Maximilian Mächler,Peter Fraunberger, Heinz Drexel (Feldkirch, AT; Triesen, LI; Berne, CH;Philadelphia, US)
15
MODERATED POSTERS B
B/5The Ceramide-Based Coronary Event Risk Test (CERT) PredictsCardiovascular Mortality in Cardiovascular Disease Patients withType 2 Diabetes Mellitus as well as in Those Without DiabetesAndreas Leiherer, Axel Muendlein, Christoph H. Saely, Rejo Laaksonen,Mitja Laaperi, Alexander Vonbank, Barbara Larcher, Arthur Mader,Maximilian Mächler, Peter Fraunberger, Heinz Drexel (Feldkirch, AT;Triesen, LI; Espoo, FL; Berne, CH; Philadelphia, US)
B/6Hand Grip Strength Predicts Mortality Independently from Type 2Diabetes and the Presence of Coronary Artery Disease Barbara Larcher, Alexander Vonbank, Christine Heinzle, Daniela Zanolin-Purin, Aarthur Mader, Maximilian Mächler, Heinz Drexel,Christoph H. Saely (Feldkirch, AT; Triesen, LI; Berne, CH; Philadelphia, US)
B/7Cardiac Magnetic Resonance Derived Global Longitudinal StrainOutperfoms Established Functional Parameters in Prognosticationafter ST-Elevation Myocardial InfarctionMagdalena Holzknecht, Martin Reindl, Christina Tiller, Ivan Lechner,Thomas Hornung, David Plappert, Gert Klug, Axel Bauer, Bernhard Metzler, Agnes Mayr, Sebastian J. Reinstadler (Innsbruck, AT)
16
MODERATED POSTERS C
TUESDAY, January 28, 2020, 12:30 – 13:30 p.m.
Moderators: P. Clemmensen (DK), S. De Waha (DE), D. Gulba (DE), S. Farhan (US), J. Wojta (AT)
C/1Prognostic Value of Health-Related Quality of Life in Patients withAcute DyspneaMaria Belkin, Desiree Wussler, Ivo Strebel, Nikola Kozhuharov, Eleni Michou, Zaid Sabti, Albina Nowak, Raphael Twerenbold, Samyut Shrestha, Dayana Flores, Thomas Nestelberger, Joan Walter,Jasper Boeddinghaus, Tobias Zimmermann, Luca Koechlin, Arnold von Eckardstein, Tobias Breidthardt, Christian Mueller (Basel, CH; Zurich, CH)
C/2External Validation of the No Objective Testing RulesPaul David Ratmann, Jasper Boeddinghaus, Pedro Lopez-Ayala, Ivo Strebel, Luca Koechlin, Thomas Nestelberger, Oscar Miro, Francisco Javier Martin-Sanchez, Desiree Wussler, Maria Rubini Gimenez,Alexandra Prepoudis, Danielle Gualandro, Dagmar Keller, Raphael Twerenbold, Christian Mueller (Basel, CH; Barcelona, ES; Madrid, ES; Zurich, CH)
C/3Clinical Characteristics of Pericarditis and Myopericarditis:Diagnosed in the Emergency Department. Factors Associated withMyocardial Involvement and the Need for HospitalizationAlexandra Prepoudis, Gemma Martínez-Nadal, Òscar Miró, Pedro Lopez Ayala, Dayana Flores, Danielle M. Gualandro, Christian Mueller, Beatriz López-Barbeito (Barcelona, ES; Rome, IT; Basel, CH)
17
MODERATED POSTERS C
C/4Prevalence of Type 2 Diabetes is Higher in Patients with Heart Failurethan in Patients with Stable Coronary Artery Disease Christoph H. Saely, Alexander Vonbank, Christine Heinzle, DanielaZanolin-Purin, Barbara Larcher, Arthur Mader, Simon Sternbauer,Maximilian Mächler, Andreas Leiherer, Axel Muendlein, Heinz Drexel(Feldkirch, AT; Triesen, LI; Berne, CH; Philadelphia, US)
C/5Type 2 Diabetes is a Strong Predictor for LDL Cholesterol TargetAchievement in Patients with Peripheral Artery Disease Simon Sternbauer, Alexander Vonbank, Christine Heinzle, Daniela Zanolin-Purin, Jörn F. Dopheide, Iris Baumgartner, Barbara Larcher, Arthur Mader, Maximilian Mächler, Andreas Leiherer,Axel Muendlein, Heinz Drexel, Christoph H. Saely (Feldkirch, AT; Triesen, LI; Berne, CH; Philadelphia, US)
C/6Weight Loss and Type 2 Diabetes are Mutually IndependentPredictors of Mortality in Patients with Established Coronary ArteryDisease Christoph H. Saely, Alexander Vonbank, Christine Heinzle, Daniela Zanolin-Purin, Barbara Larcher, Arthur Mader, Maximilian Mächler,Andreas Leiherer, Axel Muendlein, Heinz Drexel (Feldkirch, AT; Triesen, LI;Berne, CH; Philadelphia, US)
C/7Ponatinib Influences Endothelial Cell Function, CausesVasoconstriction and Impairs Blood Flow Recovery in the MouseHind Limb Ischemia Model Markus Theurl, Emir Hadzijusufovic, Andrijana Kirsch, Daniela Lener,Clemens Gutmann, Sasa Frank, Peter Valent, Rudolf Kirchmair (Innsbruck, AT; Wien, AT; Graz, AT)
18
GENERAL INFORMATION
Meeting OrganizationAssociation for the Promotion of Research in Arteriosclerosis,Thrombosis and Vascular Biology (ATVB), Mariahilferstrasse 49, A-1060 Vienna, Austria
Responsible for the Scientific ProgramKurt Huber, MD, FESC, FACC, FAHA Director, 3rd Department of Medicine Cardiology & Intensive Care Medicine, Wilhelminenhospital Montleartstrasse 37, A-1160 Vienna, Austria Tel.: (+43/1) 49 150-2301, Fax: (+43/1) 49 150-2309 E-mail: [email protected]
Congress Secretariat Congress and Study Concept GesmbH Widerhoferplatz 4/3/19, A-1090 Vienna, Austria Contact: Ms. Mag. Franziska Beckmann Phone/ (+43) 699 115 16 917E-mail: [email protected]
Medical Exhibition & Advertising Medizinische Ausstellungs- und Werbegesellschaft Freyung 6, A-1010 Vienna, Austria Contact: Ms. Sonja Chmella Phone.: (+43/1) 536 63-32, Fax: (+43/1) 535 60 16 E-mail: [email protected], www.maw.co.at
Venue Austria Trend Hotel, InnsbruckRennweg 12a, A-6020 Innsbruck, AustriaPhone: (+43-512) 2115-0, Fax. (+43-512) 2115-500E-mail: [email protected]
Congress Fee €600,– / 300.– (reduced fee for physicians in education)2-day attendance: €400.– / 200.–*1-day attendance: €200.– / 100.–*Free for students* VAT included
registration.maw.co.at/coronary20
This meeting is credited with 27 credit points for advanced training diploma(DFP) by the Austrian Medical Association (ID 66605027, www.dfpkalender.at).
GENERAL INFORMATION
19
Information for Poster PresentersYou will get notion of acceptance of your abstract latest untilJanuary 15, 2020.There will be free access to the whole meeting for poster presenters. Posters (150x90 cm height x width) should be mounted on the indicated day (Sunday, Monday, or Tuesday) latest at 9:00 AM andremoved at the evening of the same day. Poster presentation (3 min) and discussion (3 min) will take partduring the indicated poster moderation sessions.The best posters will be awarded on Tuesday, January 28, 2020 atthe end of the meeting.
www.cardio-congress.com
SPONSORS (as per printing date)
AstraZeneca
International FacultyHannes ALBER (Austria)Johann AUER (Austria)Axel BAUER (Austria)Michael BÖHM (Germany)Martin BORGGREFE (Germany)Peter CLEMMENSEN (Denmark)Harald DARIUS (Germany)John DEANFIELD (United Kingdom)Suzanne DE WAHA (Germany)Heinz DREXEL (Austria)Guy FRIEDRICH (Austria)Vladimir GASPAROVIC (Croatia)Evangelos GIANNITSIS (Germany)Bernard GERSH (USA)Christopher GRANGER (USA)Danielle GUALANDRO (Switzerland)Dietrich GULBA (Germany)
Stefan HARB (Austria)Kurt HUBER (Austria)
Carl KAULFERSCH (Austria)Steen D. KRISTENSEN (Denmark)
Gudrun LAMM (Austria)Irene LANG (Austria)
Bernhard MEIER (Switzerland)Martin MÖCKEL (Germany)
Christian MÜLLER (Switzerland)Thomas NESTELBERGER (Switzerland)
Stuart POCOCK (United Kingdom)Susanna PRICE (United Kingdom)
Anna RAB (Austria)Marcus SÄEMANN (Austria)
Helmut SCHÜHLEN (Germany)Stefanie SCHÜPKE (Germany)
Udo SECHTEM (Germany)Holger THIELE (Germany)
Hermann TOPLAK (Austria)Freek W.A. VERHEUGT (Netherlands)
Rob WELSH (Canada)Emil WESSELY (Austria)
Johann WOJTA (Austria)Uwe ZEYMER (Germany)
Andreas ZIRLIK (Austria)
www.cardio-congress.comPrinted in Austria by: ROBIDRUCKA-1200 Vienna – www.robidruck.co.at